Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Lung Neoplasms
  • Mutagenesis, Insertional
  • Receptor, Epidermal Growth Factor

abstract

  • Clinicians will frequently agree with patient-reported symptoms and performance status, and will use this information to guide documentation and symptom management. (ClinicalTrials.gov: NCT00807573).

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5228492

Digital Object Identifier (DOI)

  • 10.1177/1740774515615540

PubMed ID

  • 26542025

Additional Document Info

start page

  • 331

end page

  • 7

volume

  • 13

number

  • 3